---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-159009"
form_type: "8-K"
ticker: "DSGN"
cik: "0001807120"
company_name: "Design Therapeutics, Inc."
filed_at: "2023-06-01T23:59:59+00:00"
generated_at: "2026-06-14T09:37:36.242201+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Design Therapeutics shareholders re-elect three directors, ratify EY as auditor

## Summary
- Three Class II directors re-elected: Simeon George (47.5M for), Arsani William (49.0M), Deepa Prasad (49.0M); broker non-votes ~3.35M.
- Ratification of Ernst & Young as independent auditor for FY2023 approved: 52.5M for, 437 against, 123,262 abstentions.
- Annual meeting held May 31, 2023; 55,945,551 shares outstanding as of record date April 3, 2023.

## SEC filing metadata
- accession: 0001193125-23-159009
- form_type: 8-K
- ticker: DSGN
- cik: 0001807120
- company_name: Design Therapeutics, Inc.
- filed_at: 2023-06-01T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1807120/000119312523159009/0001193125-23-159009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1807120/000119312523159009/d348957d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-159009
- JSON: https://secwatch.observer/filing/0001193125-23-159009.json
- Plain text: https://secwatch.observer/filing/0001193125-23-159009.txt

## Key facts
- Shareholder Votes
  Design Therapeutics, Inc. shareholders approved Ratification of Selection of Independent Registered Public Accounting Firm at the 2023-05-31 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-05-31
  source text: The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 52,499,051 437 123,262 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1807120/000119312523159009/0001193125-23-159009-index.htm
- Shareholder Votes
  Design Therapeutics, Inc. shareholders approved Election of three Class II Directors at the 2023-05-31 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-05-31
  source text: The Company’s stockholders elected the three persons listed below as Class II Directors, each to serve until the Company’s 2026 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The final voting results are as follows: Votes For Votes Withheld Broker Non-Votes Simeon George, M.D. 47,533,466 1,741,637 3,347,647 Arsani William, M.D. 48,972,541 302,562 3,347,647 Deepa Prasad 48,988,793 286,310 3,347,647
  evidence_url: https://www.sec.gov/Archives/edgar/data/1807120/000119312523159009/0001193125-23-159009-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.